PDGFRB and non-small cell lung carcinoma: Orantinib (formerly TSU-68 and SU6688; Taiho Pharmaceutical Co. Ltd, Tokyo, Japan), an oral TKI that targets VEGFR2, PDGFRβ, and FGFR1, was evaluated in a phase I trial (N = 37, including five patients with squamous NSCLC) in combination with carboplatin/paclitaxel as first-line therapy for advanced NSCLC, with 13 partial responses observed among 33 evaluable patients 64.